Related Experiment Videos
Prognostic markers in resectable non-small cell lung cancer
1Division of Hematology/Oncology, Worcester-Memorial Hospital, Massachusetts.
Hematology/Oncology Clinics of North America
|June 1, 1997
Summary
Identifying prognostic markers for resectable non-small cell lung cancer (NSCLC) aids in stratifying patients by recurrence risk. This review focuses on clinically useful markers to guide post-surgery treatment strategies for early-stage NSCLC.
Area of Science:
- Oncology
- Cancer Research
- Clinical Medicine
Background:
- Resectable non-small cell lung cancer (NSCLC) management relies on identifying prognostic factors.
- Risk stratification post-resection is crucial for guiding treatment decisions.
- Numerous clinico-pathologic, serum, and molecular markers have been explored.
Purpose of the Study:
- To review prognostic markers for early-stage NSCLC.
- To identify markers with potential clinical utility in guiding post-resection treatment.
- To focus on markers relevant for treatment stratification.
Main Methods:
- Literature review of prognostic markers in resectable NSCLC.
- Classification of molecular markers (genetic, metastatic propensity, differentiation, proliferation).
- Evaluation of clinical utility for guiding post-resection strategies.
Main Results:
- Clinico-pathologic factors (tumor size, nodal status, histology) are established prognostic indicators.
- Serum tumor markers offer additional prognostic value.
- Molecular markers represent a growing area of prognostic research.
Conclusions:
- Prognostic markers are essential for personalizing treatment in early-stage NSCLC.
- A comprehensive understanding of various marker types is needed.
- Future clinical utility will depend on marker reliability and impact on treatment selection.